Search Results - "Firth, Mike A."

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity by Curtis, Nicola J, Mooney, Lorraine, Hopcroft, Lorna, Michopoulos, Filippos, Whalley, Nichola, Zhong, Haihong, Murray, Clare, Logie, Armelle, Revill, Mitchell, Byth, Kate F, Benjamin, Amanda D, Firth, Mike A, Green, Stephen, Smith, Paul D, Critchlow, Susan E

“…Tumors frequently display a glycolytic phenotype with increased flux through glycolysis and concomitant synthesis of lactate. To maintain glycolytic flux and…”
Get full text

Understanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection by Mervin, Lewis H, Cao, Qing, Barrett, Ian P, Firth, Mike A, Murray, David, McWilliams, Lisa, Haddrick, Malcolm, Wigglesworth, Mark, Engkvist, Ola, Bender, Andreas

“…While mechanisms of cytotoxicity and cytostaticity have been studied extensively from the biological side, relatively little is currently understood regarding…”
Get full text

In vivo CRISPR editing with no detectable genome-wide off-target mutations by Akcakaya, Pinar, Bobbin, Maggie L., Guo, Jimmy A., Malagon-Lopez, Jose, Clement, Kendell, Garcia, Sara P., Fellows, Mick D., Porritt, Michelle J., Firth, Mike A., Carreras, Alba, Baccega, Tania, Seeliger, Frank, Bjursell, Mikael, Tsai, Shengdar Q., Nguyen, Nhu T., Nitsch, Roberto, Mayr, Lorenz M., Pinello, Luca, Bohlooly-Y, Mohammad, Aryee, Martin J., Maresca, Marcello, Joung, J. Keith

“…CRISPR–Cas genome-editing nucleases hold substantial promise for developing human therapeutic applications 1 – 6 but identifying unwanted off-target mutations…”
Get full text

Orthologue chemical space and its influence on target prediction by Mervin, Lewis H, Bulusu, Krishna C, Kalash, Leen, Afzal, Avid M, Svensson, Fredrik, Firth, Mike A, Barrett, Ian, Engkvist, Ola, Bender, Andreas

“…Abstract Motivation In silico approaches often fail to utilize bioactivity data available for orthologous targets due to insufficient evidence highlighting the…”
Get full text

Targeted Metabolic Profiling of the Tg197 Mouse Model Reveals Itaconic Acid as a Marker of Rheumatoid Arthritis by Michopoulos, Filippos, Karagianni, Niki, Whalley, Nichola M, Firth, Mike A, Nikolaou, Christoforos, Wilson, Ian D, Critchlow, Susan E, Kollias, George, Theodoridis, Georgios A

“…Rheumatoid arthritis is a progressive, highly debilitating disease where early diagnosis, enabling rapid clinical intervention, would provide obvious benefits…”
Get full text

In vivo CRISPR editing with no detectable genomewide off-target mutations by Akcakaya, Pinar, Bobbin, Maggie L, Guo, Jimmy A, Malagon-Lopez, Jose, Clement, Kendell, Garcia, Sara P, Fellows, Mick D, Porritt, Michelle J, Firth, Mike A, Carreras, Alba, Baccega, Tania, Seeliger, Frank, Bjursell, Mikael, Tsai, Shengdar Q, Nguyen, Nhu T, Nitsch, Roberto, Mayr, Lorenz M, Pinello, Luca, Bohlooly-Y, Mohammad, Aryee, Martin J, Maresca, Marcello, Joung, J Keith

“…CRISPR-Cas genome-editing nucleases hold substantial promise for developing human therapeutic applications but identifying unwanted off-target mutations is…”
Get full text

MOLMAKER:  De Novo Generation of 3D Databases for Use in Drug Design by Clark, David E, Firth, Mike A, Murray, Christopher W

“…A program, MOLMAKER, is described which, in conjunction with a 2D−3D conversion program and 3D database software, can generate de novo 3D databases to aid in…”
Get full text